NCCN Categories of Evidence and Consensus
Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
All recommendations are category 2A unless otherwise noted.
Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Cheng L, Eng C, Nieman LZ et al.. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol 2011;34:573–580.
Eheman C, Henley SJ, Ballard-Barbash R et al.. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012;118:2338–2366.
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212–236.
Gunderson LL, Jessup JM, Sargent DJ et al.. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010;28:264–271.
Levin B, Lieberman DA, McFarland B et al.. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58:130–160.
- Search Google Scholar
- Export Citation
. Levin B Lieberman DA McFarland B Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58: 130– 160.
Rex DK, Johnson DA, Anderson JC et al.. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009;104:739–750.
U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149:627–637.
Centers for Disease Control and Prevention (CDC). Cancer screening - United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61:41–45.
Warren JL, Klabunde CN, Mariotto AB et al.. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med 2009;150:849–857, W152.
Citarda F, Tomaselli G, Capocaccia R et al.. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 2001;48:812–815.
Jacob BJ, Moineddin R, Sutradhar R et al.. Effect of colonoscopy on colorectal cancer incidence and mortality: an instrumental variable analysis. Gastrointest Endosc 2012;76:355–364 e351.
Winawer SJ, Zauber AG, Ho MN et al.. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977–1981.
Manser CN, Bachmann LM, Brunner J et al.. Colonoscopy screening markedly reduces the occurrence of colon carcinomas and carcinoma-related death: a closed cohort study. Gastrointest Endosc 2012;76:110–117.
Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med 1995;123:904–910.
Rabeneck L, Paszat LF, Saskin R, Stukel TA. Association between colonoscopy rates and colorectal cancer mortality. Am J Gastroenterol 2010;105:1627–1632.
Baxter NN, Goldwasser MA, Paszat LF et al.. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009;150:1–8.
Barclay RL, Vicari JJ, Doughty AS et al.. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 2006;355:2533–2541.
Radaelli F, Meucci G, Sgroi G, Minoli G. Technical performance of colonoscopy: the key role of sedation/analgesia and other quality indicators. Am J Gastroenterol 2008;103:1122–1130.
Kahi CJ, Imperiale TF, Juliar BE, Rex DK. Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol 2009;7:770–775; quiz 711.
Zauber AG, Winawer SJ, O’Brien MJ et al.. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012;366:687–696.
Brenner H, Chang-Claude J, Seiler CM et al.. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 2011;154:22–30.
Baxter NN, Warren JL, Barrett MJ et al.. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol 2012;30:2664–2669.
Quintero E, Castells A, Bujanda L et al.. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012;366:697–706.
Hassan C, Giorgi Rossi P, Camilloni L et al.. Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther 2012;36:929–940.
Kaminski MF, Regula J, Kraszewska E et al.. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010;362:1795–1803.
Lieberman D, Nadel M, Smith RA et al.. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc 2007;65:757–766.
Rex DK, Cummings OW, Helper DJ et al.. 5-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons [see comment]. Gastroenterology 1996;111:1178–1181.
Imperiale TF, Glowinski EA, Lin-Cooper C et al.. Five-year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med 2008;359:1218–1224.
Lieberman DA, Weiss DG, Harford WV et al.. Five-year colon surveillance after screening colonoscopy. Gastroenterology 2007;133:1077–1085.
Singh H, Turner D, Xue L et al.. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA 2006;295:2366–2373.
Brenner H, Chang-Claude J, Seiler CM et al.. Does a negative screening colonoscopy ever need to be repeated? Gut 2006;55:1145–1150.
Brenner H, Chang-Claude J, Seiler CM, Hoffmeister M. Long-term risk of colorectal cancer after negative colonoscopy. J Clin Oncol 2011;29:3761–3767.
Newcomb PA, Norfleet RG, Storer BE et al.. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992;84:1572–1575.
Atkin WS, Edwards R, Kralj-Hans I et al.. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624–1633.
Segnan N, Armaroli P, Bonelli L et al.. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. J Natl Cancer Inst 2011;103:1310–1322.
Hoff G, Grotmol T, Skovlund E, Bretthauer M. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 2009;338:b1846.
Schoen RE, Pinsky PF, Weissfeld JL et al.. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012;366:2345–2357.
Weissfeld JL, Schoen RE, Pinsky PF et al.. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst 2005;97:989–997.
Weissfeld JL, Schoen RE, Pinsky PF et al.. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst 2012;104:280–289.
Elmunzer BJ, Hayward RA, Schoenfeld PS et al.. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 2012;9:e1001352.
Wang YR, Cangemi JR, Loftus EV Jr, Picco MF. Risk of colorectal cancer after colonoscopy compared with flexible sigmoidoscopy or no lower endoscopy among older patients in the United States, 1998-2005. Mayo Clin Proc 2013;88:464–470.
Doubeni CA, Weinmann S, Adams K et al.. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med 2013;158:312–320.
Schoen RE, Pinsky PF, Weissfeld JL et al.. Colorectal cancers not detected by screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Gastrointest Endosc 2012;75:612–620.
Kim DH, Pickhardt PJ, Taylor AJ, Menias CO. Imaging evaluation of complications at optical colonoscopy. Curr Probl Diagn Radiol 2008;37:165–177.
Whitlock EP, Lin JS, Liles E et al.. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:638–658.
Johnson CD, Chen MH, Toledano AY et al.. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 2008;359:1207–1217.
Johnson CD, Toledano AY, Herman BA et al.. Computerized tomographic colonography: performance evaluation in a retrospective multicenter setting. Gastroenterology 2003;125:688–695.
Rockey DC, Paulson E, Niedzwiecki D et al.. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet 2005;365:305–311.
Pickhardt PJ, Choi JR, Hwang I et al.. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003;349:2191–2200.
Kim DH, Pickhardt PJ, Taylor AJ et al.. CT colonography versus colonoscopy for the detection of advanced neoplasia. N Engl J Med 2007;357:1403–1412.
Halligan S, Altman DG, Taylor SA et al.. CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting. Radiology 2005;237:893–904.
Pickhardt PJ, Hassan C, Halligan S, Marmo R. Colorectal cancer: CT colonography and colonoscopy for detection—systematic review and meta-analysis. Radiology 2011;259:393–405.
de Haan MC, van Gelder RE, Graser A et al.. Diagnostic value of CT-colonography as compared to colonoscopy in an asymptomatic screening population: a meta-analysis. Eur Radiol 2011;21:1747–1763.
Stoop EM, de Haan MC, de Wijkerslooth TR et al.. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol 2012;13:55–64.
Zalis ME, Blake MA, Cai W et al.. Diagnostic accuracy of laxative-free computed tomographic colonography for detection of adenomatous polyps in asymptomatic adults: a prospective evaluation. Ann Intern Med 2012;156:692–702.
Fletcher JG, Chen MH, Herman BA et al.. Can radiologist training and testing ensure high performance in CT colonography? Lessons from the National CT Colonography Trial. AJR Am J Roentgenol 2010;195:117–125.
Berrington de Gonzalez A, Kim KP, Yee J. CT colonography: perforation rates and potential radiation risks. Gastrointest Endosc Clin N Am 2010;20:279–291.
ACR Practice Guideline for the Performance of Coputed Tomography (CT) Colonography in Adults. 2009. Available at: http://www.acr.org/~/media/ACR/Documents/PGTS/guidelines/CT_Colonography.pdf. Accessed June 1, 2011.
Collins JF, Lieberman DA, Durbin TE, Weiss DG. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005;142:81–85.
Nadel MR, Berkowitz Z, Klabunde CN et al.. Fecal occult blood testing beliefs and practices of U.S. primary care physicians: serious deviations from evidence-based recommendations. J Gen Intern Med 2010;25:833–839.
Hardcastle JD, Chamberlain JO, Robinson MH et al.. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472–1477.
Kronborg O, Fenger C, Olsen J et al.. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467–1471.
Mandel JS, Bond JH, Church TR et al.. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365–1371.
Scholefield JH, Moss SM, Mangham CM et al.. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 2012;61:1036–1040.
Hewitson P, Glasziou P, Watson E et al.. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008;103:1541–1549.
Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155–159.
Lee TJ, Clifford GM, Rajasekhar P et al.. High yield of colorectal neoplasia detected by colonoscopy following a positive faecal occult blood test in the NHS Bowel Cancer Screening Programme. J Med Screen 2011;18:82–86.
Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009;150:162–169.
Allison JE, Sakoda LC, Levin TR et al.. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007;99:1462–1470.
Hol L, Van Leerdam ME, Van Ballegooijen M et al.. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59:62–68.
Park DI, Ryu S, Kim YH et al.. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010;105:2017–2025.
Parra-Blanco A, Gimeno-Garcia AZ, Quintero E et al.. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol 2010;45:703–712.
Rabeneck L, Rumble RB, Thompson F et al.. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 2012;26:131–147.
Imperiale TF, Ransohoff DF, Itzkowitz SH et al.. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704–2714.
Ahlquist DA, Sargent DJ, Loprinzi CL et al.. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008;149:441–450, W481.
Ahlquist DA, Zou H, Domanico M et al.. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012;142:248–256; quiz e225-246.
Ned RM, Melillo S, Marrone M. Fecal DNA testing for colorectal cancer screening: the ColoSure test. PLoS Curr 2011;3:RRN1220.
Kadouri L, Hubert A, Rotenberg Y et al.. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet 2007;44:467–471.
Luo W, Cao Y, Liao C, Gao F. Diabetes mellitus and the incidence and mortality of colorectal cancer: a meta-analysis of 24 cohort studies. Colorectal Dis 2012;14:1301–1312.
Theuer CP, Wagner JL, Taylor TH et al.. Racial and ethnic colorectal cancer patterns affect the cost-effectiveness of colorectal cancer screening in the United States. Gastroenterology 2001;120:848–856.
Agrawal S, Bhupinderjit A, Bhutani MS et al.. Colorectal cancer in African Americans. Am J Gastroenterol 2005;100:515–523; discussion 514.
Knudsen AB, Hur C, Gazelle GS et al.. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med 2012;157:611–620.
Heresbach D, Barrioz T, Lapalus MG et al.. Miss rate for colorectal neoplastic polyps: a prospective multicenter study of back-to-back video colonoscopies. Endoscopy 2008;40:284–290.
Alvarez C, Andreu M, Castells A et al.. Relationship of colonoscopy-detected serrated polyps with synchronous advanced neoplasia in average-risk individuals. Gastrointest Endosc 2013;78:333–341.
Rex DK, Ahnen DJ, Baron JA et al.. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012;107:1315–1329; quiz 1314, 1330.
Chow E, Lipton L, Lynch E et al.. Hyperplastic polyposis syndrome: phenotypic presentations and the role of MBD4 and MYH. Gastroenterology 2006;131:30–39.
Rubio CA, Stemme S, Jaramillo E, Lindblom A. Hyperplastic polyposis coli syndrome and colorectal carcinoma. Endoscopy 2006;38:266–270.
Yeoman A, Young J, Arnold J et al.. Hyperplastic polyposis in the New Zealand population: a condition associated with increased colorectal cancer risk and European ancestry. N Z Med J 2007;120:U2827.
Ferrandez A, Samowitz W, DiSario JA, Burt RW. Phenotypic characteristics and risk of cancer development in hyperplastic polyposis: case series and literature review. Am J Gastroenterol 2004;99:2012–2018.
Leggett BA, Devereaux B, Biden K et al.. Hyperplastic polyposis: association with colorectal cancer. Am J Surg Pathol 2001;25:177–184.
Winawer SJ, Zauber AG, Fletcher RH et al.. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin 2006;56:143–159; quiz 184-145.
Lieberman DA, Rex DK, Winawer SJ et al.. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012;143:844–857.
Robertson DJ, Burke CA, Welch HG et al.. Using the results of a baseline and a surveillance colonoscopy to predict recurrent adenomas with high-risk characteristics. Ann Intern Med 2009;151:103–109.
O’Brien MJ, Winawer SJ, Zauber AG et al.. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990;98:371–379.
Golembeski C, McKenna B, Appelman HD. Advanced adenomas: pathologists don’t agree [abstract]. Modern Pathology 2007;20:Abstract 115A.
Brenner H, Chang-Claude J, Rickert A et al.. Risk of colorectal cancer after detection and removal of adenomas at colonoscopy: population-based case-control study. J Clin Oncol 2012;30:2969–2976.
Walsh RM, Ackroyd FW, Shellito PC. Endoscopic resection of large sessile colorectal polyps. Gastrointest Endosc 1992;38:303–309.
Rex DK, Kahi CJ, Levin B et al.. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin 2006;56:160–167; quiz 185-166.
Rodriguez-Moranta F, Salo J, Arcusa A et al.. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol 2006;24:386–393.
Sargent DJ, Wieand HS, Haller DG et al.. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664–8670.
Shureiqi I, Cooksley CD, Morris J et al.. Effect of age on risk of second primary colorectal cancer. J Natl Cancer Inst 2001;93:1264–1266.
Hoffman JP, Riley L, Carp NZ, Litwin S. Isolated locally recurrent rectal cancer: a review of incidence, presentation, and management. Semin Oncol 1993;20:506–519.
Lowy AM, Rich TA, Skibber JM et al.. Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma. Ann Surg 1996;223:177–185.
Yu TK, Bhosale PR, Crane CH et al.. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2008;71:1175–1180.
Green RJ, Metlay JP, Propert K et al.. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 2002;136:261–269.
Pietra N, Sarli L, Costi R et al.. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum 1998;41:1127–1133.
Secco GB, Fardelli R, Gianquinto D et al.. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol 2002;28:418–423.
Desch CE, Benson AB, Somerfield MR et al.. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005;23:8512–8519.
Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007:CD002200.
Renehan AG, Egger M, Saunders MP, O’Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002;324:813–813.
Tepper JE, O’Connell M, Niedzwiecki D et al.. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of intergroup 0114. J Clin Oncol 2002;20:1744–1750.
Guyot F, Faivre J, Manfredi S et al.. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol 2005;16:756–761.
Pfister DG, Benson AB 3rd, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med 2004;350:2375–2382.
Beaugerie L, Svrcek M, Seksik P et al.. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013;145:166–175.
Lutgens MW, van Oijen MG, van der Heijden GJ et al.. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013;19:789–799.
Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526–535.
Farraye FA, Odze RD, Eaden J et al.. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010;138:738–745.
Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501–523; quiz 524.
Neumann H, Vieth M, Langner C et al.. Cancer risk in IBD: how to diagnose and how to manage DALM and ALM. World J Gastroenterol 2011;17:3184–3191.
Umar A, Boland CR, Terdiman JP et al.. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261–268.
Taylor DP, Burt RW, Williams MS et al.. Population-based family history-specific risks for colorectal cancer: a constellation approach. Gastroenterology 2010;138:877–885.
Imperiale TF, Ransohoff DF. Risk for colorectal cancer in persons with a family history of adenomatous polyps: a systematic review. Ann Intern Med 2012;156:703–709.
Aaltonen LA, Salovaara R, Kristo P et al.. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481–1487.
Hampel H, Frankel WL, Martin E et al.. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851–1860.
Hampel H, Frankel WL, Martin E et al.. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008;26:5783–5788.
Kempers MJ, Kuiper RP, Ockeloen CW et al.. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 2011;12:49–55.
Rumilla K, Schowalter KV, Lindor NM et al.. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn 2011;13:93–99.
Vasen HF, Wijnen JT, Menko FH et al.. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020–1027.
Aaltonen LA, Peltomaki P, Mecklin JP et al.. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994;54:1645–1648.
Moslein G, Tester DJ, Lindor NM et al.. Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet 1996;5:1245–1252.
Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995;108:1405–1411.
Lindor NM, Petersen GM, Hadley DW et al.. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006;296:1507–1517.
Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453–1456.
Vasen HF. Clinical diagnosis and management of hereditary colorectal cancer syndromes. J Clin Oncol 2000;18(21 Suppl):81S–92S.
Barnetson RA, Tenesa A, Farrington SM et al.. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006;354:2751–2763.
Rodriguez-Bigas MA, Boland CR, Hamilton SR et al.. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758–1762.
Raedle J, Trojan J, Brieger A et al.. Bethesda guidelines: relation to microsatellite instability and MLH1 promoter methylation in patients with colorectal cancer. Ann Intern Med 2001;135:566–576.
Pinol V, Castells A, Andreu M et al.. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005;293:1986–1994.
Ramsey SD, Clarke L, Etzioni R et al.. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 2001;135:577–588.
Balmana J, Stockwell DH, Steyerberg EW et al.. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 2006;296:1469–1478.
Kastrinos F, Steyerberg EW, Mercado R et al.. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 2011;140:73–81.
Beamer LC, Grant ML, Espenschied CR et al.. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 2012;30:1058–1063.
Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35–41.
Ladabaum U, Wang G, Terdiman J et al.. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011;155:69–79.
Palomaki GE, McClain MR, Melillo S et al.. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:42–65.
Heald B, Plesec T, Liu X et al.. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol 2013;31:1336–1340.
Moreira L, Balaguer F, Lindor N et al.. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012;308:1555–1565.
Boland CR, Shike M. Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology 2010;138:2197 e2191-2197.
Hendriks YM, de Jong AE, Morreau H et al.. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin 2006;56:213–225.
Caldes T, Godino J, Sanchez A et al.. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer. Oncol Rep 2004;12:621–629.
Vasen HF, Hendriks Y, de Jong AE et al.. Identification of HNPCC by molecular analysis of colorectal and endometrial tumors. Dis Markers 2004;20:207–213.
Hampel H, Frankel W, Panescu J et al.. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006;66:7810–7817.
Lindor NM, Burgart LJ, Leontovich O et al.. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002;20:1043–1048.
Reyes CM, Allen BA, Terdiman JP, Wilson LS. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer 2002;95:1848–1856.
Shia J, Klimstra DS, Nafa K et al.. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 2005;29:96–104.
Pino MS, Chung DC. Application of molecular diagnostics for the detection of Lynch syndrome. Expert Rev Mol Diagn 2010;10:651–665.
Lagerstedt Robinson K, Liu T, Vandrovcova J et al.. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst 2007;99:291–299.
Yurgelun MB, Goel A, Hornick JL et al.. Microsatellite instability and DNA mismatch repair protein deficiency in lynch syndrome colorectal polyps. Cancer Prev Res (Phila) 2012;5:574–582.
Dinh TA, Rosner BI, Atwood JC et al.. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) 2011;4:9–22.
Ward RL, Hicks S, Hawkins NJ. Population-based molecular screening for Lynch syndrome: implications for personalized medicine. J Clin Oncol 2013;31:2554–2562.
Bonadona V, Bonaiti B, Olschwang S et al.. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305:2304–2310.
Engel C, Loeffler M, Steinke V et al.. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012;30:4409–4415.
Kohlmann W, Gruber S. Lynch syndrome. In: Pagon RA, Adam MP, Bird TD et al., eds. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 1993–2013.
Watson P, Vasen HF, Mecklin JP et al.. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008;123:444–449.
Win AK, Young JP, Lindor NM et al.. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012;30:958–964.
Senter L, Clendenning M, Sotamaa K et al.. The clinical phenotype of Lynch syndrome due to germline PMS2 mutations. Gastroenterology 2008;135:419–428.
Chen LM, Yang KY, Little SE et al.. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol 2007;110:18–25.
Schmeler KM, Lynch HT, Chen LM et al.. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261–269.
Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand 2011;90:437–444.
Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K et al.. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 2009;27:4793–4797.
Renkonen-Sinisalo L, Butzow R, Leminen A et al.. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007;120:821–824.
Rijcken FE, Mourits MJ, Kleibeuker JH et al.. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003;91:74–80.
Dove-Edwin I, Boks D, Goff S et al.. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002;94:1708–1712.
Capelle LG, Van Grieken NC, Lingsma HF et al.. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010;138:487–492.
ten Kate GL, Kleibeuker JH, Nagengast FM et al.. Is surveillance of the small bowel indicated for Lynch syndrome families? Gut 2007;56:1198–1201.
Koornstra JJ, Kleibeuker JH, Vasen HF. Small-bowel cancer in Lynch syndrome: is it time for surveillance? Lancet Oncol 2008;9:901–905.
Renkonen-Sinisalo L, Sipponen P, Aarnio M et al.. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol 2002;37:574–577.
Vasen HF, Blanco I, Aktan-Collan K et al.. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013;62:812–823.
Skeldon SC, Semotiuk K, Aronson M et al.. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol 2013;63:379–385.
Burn J, Gerdes AM, Macrae F et al.. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011;378:2081–2087.
Jankowski J, Barr H, Moayyedi P. Does aspirin really reduce the risk of colon cancer? Lancet 2012;379:1586–1587; author reply 1587.